Postinflammatory hyperpigmentation: Evolving combination treatment strategies

Cutis

Volumn 78, Issue 2 SUPPL., 2006, Pages 6-19

  Taylor, Susan C ^a,b   Burgess, Cheryl M ^c,d   Callender, Valerie D ^e,f   Fu, Jan ^g   Rendon, Marta I ^h,i,j   Roberts, Wendy E ^k,l   Shalita, Alan R ^m,n,o  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c Center for Dermatology and Dermatologic Surgery   (United States)

^d GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^e HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f Callender Skin and Laser Center   (United States)

^g Dermatology and Aesthetic Center ^*

^h Dermatology and Aesthetic Center   (United States)

ⁱ UNIVERSITY OF MIAMI   (United States)

^j FLORIDA ATLANTIC UNIVERSITY   (United States)

^k LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l Desert Dermatology Medical Associates   (United States)

^m Downstate Health Sciences University   (United States)

ⁿ University Hospital of Brooklyn   (United States)

^o VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; DERMATOLOGICAL AGENT; HYDROQUINONE; HYDROQUINONE DERIVATIVE; RETINOID;

ADOLESCENT; ADULT; CASE REPORT; DERMATITIS; FEMALE; HUMAN; HYPERPIGMENTATION; MALE; MULTIMODALITY CANCER THERAPY; REVIEW; SKIN ABRASION;

ADOLESCENT; ADULT; ANTIOXIDANTS; COMBINED MODALITY THERAPY; DERMABRASION; DERMATITIS; DERMATOLOGIC AGENTS; FEMALE; HUMANS; HYDROQUINONES; HYPERPIGMENTATION; MALE; RETINOIDS;

EID: 33749030491     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Grimes PE. Disorders of pigmentation: disorders of hyperpigmentation. ACP Med Online. Available at: www.medscape.com/viewarticle/529785. Accessed May 15, 2005.
2. Bose SK, Ortonne JP. Pigmentation: dyschromia. In: Baran R, Maibach HI, eds. Cosmetic Dermatology. London, England: Martin Dunitz; 1994:277-298.
3. Ruiz-Maldonado R, de la Luz Orozco-Covarrubias M. Postinflammatory hypopigmentation and hyperpigmentation. Sem Cutan Med Surg. 1996;16(1):36-43.
4. Stulberg DL, Clark N, Tovey D. Common hyperpigmentation disorders in adults: part II. melanoma, seborrheic keratoses, acanthosis nigricans, melasma, diabetic dermopathy, tinea versicolor, and postinflammatory hyperpigmentation. Am Fam Physician. 2003;68:1963-1968.
5. Tomita Y, Maeda K, Tagami H. Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation. Pigment Cell Res. 1992;5(5 pt 2):357-361.
6. Gold P. An assessment of the histopathologic features of postinflammatory hyperpigmentation [abstract]. J Am Acad Dermatol. 2006;54(suppl):AB195.
7. Veysey E, Ratnavel R. Facial acanthosis nigricans associated with obesity. Clin Exp Dermatol. 2005;30:437-439.
8. Rendon MI, Sontheimer RD, Bergstreser PR. Acanthosis nigricans: a cutaneous marker of tissue resistance to insulin. J Am Acad Dermatol. 1989;21(3 pt 1):461-469.
9. Ten S, New M, Maclaren N. Clinical review 130: Addison's disease 2001. J Clin Endocrinol Metab. 2001;86:2909-2922.
10. Levin CY, Maibach H. Exogenous ochronosis, an update on clinical features, causative agents and treatment options. Am J Clin Dermatol. 2001;2:213-217.
11. Salim T, Shenoi SD, Balachandran C, et al. Lichen amyloidosus: a study of clinical, histopathologic and immunofluorescence findings in 30 cases. Indian J Dermatol Venereol Leprol. 2005;71:166-169.
12. Khoo BP, Tay YK. Lichen amyloidosus: a bullous variant. Ann Acad Med Singapore. 2000;29:105-107.
13. Eswaramoorthy V, Kaur I, Das A, et al. Macular amyloidosis: etiological factors. J Dermatol. 1999;26:305-310.
14. Ozkaya-Bayazit E, Kavak A, Gungor H, et al. Intermittent use of optical dimethyl sulfoxide in macular and papular amyloidosis. Int J Dermatol. 1998;37:949-954.
15. Rasi A, Khatami A, Javaheri SM. Macular amyloidosis: an assessment of prevalence, sex, and age. Int J Dermatol. 2004;43:898-899.
16. Scully C, el-Kom M. Lichen planus: review and update on pathogenesis. J Oral Pathol. 1985;14:431-458.
17. Goldblum RM. Lichen planus. Skinmed. 2002;1:52-53.
18. de Moura Castro Jacques C, Pereira ALC, Cabral MG, et al. Oral lichen planus part I: epidemiology, clinics, etiology, immunopathology, and diagnosis. Skinmed. 2003;2:342-349.
19. Taylor SC, Callender VD. A multicenter, 12-week, phase 3b trial: a combination solution of mequinol 2%/tretinoin 0.01% vs hydroquinone 4% cream in the treatment of mild to moderate postinflammatory hyperpigmentation [abstract]. J Am Acad Dermatol. 2006;54(suppl):AB194.
20. Callender VD. A small open-label study of a 2% 4-hydroxyanisole and 0.01% tretinoin solution for the treatment of postinflammatory hyperpigmentation. J Am Acad Dermatol. 2004;50(suppl):P175.
21. Nair X, Parab P, Suhr L, et al. Combination of 4-hydroxyanisole and all-trans retinoic acid produces synergistic skin depigmentation in swine. J Invest Dermatol. 1993;101:145-149.
22. Downie JB. Treatment of solar lentigines with mequinol/tretinoin: report of 3 cases. Cosmet Dermatol. 2004;17:166-168.
23. Fleischer AB Jr, Schwartzel EH, Colby SI, et al. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesion in two double-blind multicenter clinical studies. J Am Acad Dermatol. 2000;42:459-467.
24. Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis. 2004;74:362-368.
25. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77:45-50.
26. Halder RM, Richards GM. Topical agents used in the management of hyperpigmentation. Skin Therapy Lett. 2004;9(6):1-3.
27. Balina LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30:893-895.
28. Amer M, Metwalli M. Topical hydroquinone in the treatment of some hyperpigmentary disorders. Int J Dermatol. 1998;37:449-450.
29. Espinal-Perez LE, Moncada B, Castanedo-Cazaares JP. A double-blind randomized trial of 5% ascorbic acid versus 4% hydroquinone in melasma. Int J Dermatol. 2004;43:604-607.
30. Haddad AL, Matos LF, Brunstein F, et al. A clinical prospective, randomized double-blind trial comparing skin whitening complex with hydroquinone versus placebo in the treatment of melasma. Int J Dermatol. 2003;42:153-156.
31. Westerhof W, Kooyers TJ. Hydroquinone and its analogues in dermatology-a potential health risk. J Cosmet Dermatol. 2005;4:55-59.
32. James WD. Acne. N Engl J Med. 2005;352:1463-1472.
33. Rafal ES, Griffiths CEM, Ditre CM, et al. Topical tretinoin (retinoic acid) treatment for liver spots associated with photodamage. N Engl J Med. 1992;326:368-374.
34. Bulengo-Ransby SM, Griffiths CEM, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328:1438-1443.
35. Jacyk WK. Adapalene in the treatment of African patients. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):37-42.
36. Grimes PE. The safety and efficacy of salicylic acid chemical peels in dark racial-ethnic groups. Dermatol Surg. 1999;25:18-22.
37. Burns RL, Prevost-Blank PL, Lawry MA, et al. Glycolic acid peels for postinflammatory hyperpigmentation in black patients, a comparative study. Dermatol Surg. 1997;23:171-174.
38. Cotellessa C, Peris K, Fargnoli MC, et al. Microabrasion versus microabrasion followed by 15% trichloroacetic acid for treatment of cutaneous hyperpigmentations in adult females. Dermatol Surg. 2003;29:352-356.
39. Kunachak S, Leelaudomlipi P, Wongwaisayawan S. Dermabrasion: a curative treatment for melasma. Aesthetic Plast Surg. 2001;25:114-117.
40. Guevara IL, Pandya AG. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol. 2003;42:966-972.
41. Grimes P, Kelly AP, Torok H, et al. Community-based trial of a triple-combination agent for the treatment of facial melasma. Cutis. 2006;77:177-184.
42. Draelos ZD. Novel approach to treatment of hyperpigmented photodamaged skin: 4% hydroquinone/0.3% retinol versus tretinoin 0.05% emollient cream. Dermatol Surg. 2005;31(7 part 2):799-804.
43. Momosawa A, Yoshimura K, Uchida G, et al. Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for acquired dermal melanocytosis. Dermatol Surg. 2003;29:1001-1007.
44. Lee GY, Kim HJ, Whang KK. The effect of combination treatment of the recalcitrant pigmentary disorders with pigmented laser and chemical peeling. Dermatol Surg. 2002;28:1120-1123.
45. Rendon MI, Benitez AL. Use of a triple-combination agent and various procedures for treatment of melasma. Cosmet Dermatol. 2005;18:495-498, 501-503.
46. Jarratt M. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis. 2004;74:319-322.
47. Rendon MI, Benitez AL, Gaviria JI. Treatment of solar lentigines with mequinol/tretinoin in combination with a pigment-specific laser: 2 case reports. Cosmet Dermatol. 2004;17:223-226.
48. Hexsel DM. A study on the use of mequinol/tretinoin to prevent the reappearance of solar lentigines in patients previously treated with chemical peels and cryotherapy. Cosmet Dermatol. 2004;17:269-272, 274.
49. Ast E. The management of solar lentigines: the value of combination therapy. Cosmet Dermatol. 2004;17:421-425.
50. Piacquadio D, Farris P, Downie J, et al. Mequinol 2%/tretinoin 0.01% solution monotherapy and combination treatment of solar lentigines and postinflammatory hyperpigmentation. J Am Acad Dermatol. 2004;52(suppl):P145.
51. Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72:67-72.